Tvardi reports Q3 2026 results, preps TTI-109 move into ulcerative colitis trial
Houston biotech says Phase 1 data support advancing its STAT3 inhibitor prodrug into UC, while HCC topline data from TTI-101 are expected early in Q1 2027.
SEC filing
2 stories
Houston biotech says Phase 1 data support advancing its STAT3 inhibitor prodrug into UC, while HCC topline data from TTI-101 are expected early in Q1 2027.
SEC filing